Welcome to our dedicated page for Lifemd news (Ticker: LFMDP), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. (LFMDP) provides a centralized news hub for investors and healthcare professionals tracking advancements in integrated telehealth solutions. This resource aggregates official announcements regarding service expansions, technology innovations, and operational milestones within LifeMD's HIPAA-compliant ecosystem.
Access timely updates on virtual care initiatives, including developments in remote diagnostics, digital prescription systems, and secure provider-patient communication platforms. The curated news collection enables stakeholders to monitor strategic partnerships, regulatory compliance achievements, and enhancements to the company's clinician-centric EMR infrastructure.
All content reflects LifeMD's commitment to advancing accessible healthcare through AES-encrypted telemedicine services and custom diagnostic equipment. Bookmark this page for verified updates about operational developments that shape the company's position in the digital health sector.
LifeMD (Nasdaq: LFMD), a leading virtual primary care services provider, has announced its participation in the Mizuho Health Care Conference: Medical Device, Services, Technology and Distribution. The event will take place on December 11, 2024 at the Sofitel New York.
The company's management team will be available for one-on-one meetings with investors throughout the conference day. Institutional investors who wish to meet with LifeMD management at the conference should coordinate through their Mizuho Securities representative.
LifeMD (Nasdaq: LFMD), a leading virtual primary care services provider, has announced its participation in three major investor conferences this November. The company will attend the Craig-Hallum 15th Annual Alpha Select Conference on November 19 at the Sheraton NY Times Square Hotel, the Stephens NASH24 Conference on November 20 at the Grand Hyatt Nashville, and the BTIG Digital Health Forum on November 25. At BTIG, management will participate in a panel discussion titled 'Primary Care is the Solution' at 10:00 a.m. Eastern time. The management team will be available for one-on-one meetings with investors at all three events.
LifeMD (NASDAQ: LFMD) reported strong Q3 2024 results with total revenues increasing 38% year-over-year to $53.4 million, driven by 65% growth in telehealth revenue. The company achieved a record gross margin of 90.6% and Adjusted EBITDA of $3.7 million. Telehealth subscribers grew 30% to 269,000, while telehealth adjusted EBITDA reached $2.5 million. The company maintained strong cash position of $37.6 million and generated $6.2 million in operating cash flow. For Q4 2024, LifeMD expects revenues between $57-58 million and adjusted EBITDA of $6.5-7.0 million.
LifeMD (NASDAQ: LFMD) has launched its state-of-the-art affiliated pharmacy in Lancaster, PA, completing its end-to-end telehealth platform. The 22,500-square-foot facility can process up to 5,000 daily prescriptions and is expected to be licensed across all 50 states, DC, and Puerto Rico by year-end. This integration is projected to generate $5 million in annualized expense savings. The pharmacy enhances LifeMD's vertically integrated platform, which includes proprietary virtual-care technology, a 50-state medical group, and a U.S.-based patient care center. The facility will enable personalized care packages and bundled shipments combining prescriptions and wellness products.
LifeMD (Nasdaq: LFMD), a virtual primary care services provider, has scheduled its third quarter 2024 financial results announcement for November 7, 2024, after U.S. market close. The company will host a conference call at 4:30 p.m. Eastern time, accessible via toll-free (800-717-1738) and international (646-307-1865) dial-in numbers, with conference ID 73461.
LifeMD, Inc. (Nasdaq: LFMD), a leading virtual primary care services provider, has announced a quarterly cash dividend for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP). The dividend, authorized by the company's Board of Directors, amounts to $0.5546875 per share. Shareholders of record as of the close of business on October 4, 2024, will receive the dividend payment on October 15, 2024. This announcement demonstrates LifeMD's commitment to providing returns to its preferred stockholders.
LifeMD (Nasdaq: LFMD) has announced major enhancements to its weight management program, expanding patient access to branded GLP-1 therapies and introducing new treatment options. The company has implemented a real-time electronic benefit verification program and partnered with an AI-powered platform to optimize prior authorization submissions. These improvements are estimated to increase LifeMD's addressable weight loss market by 15%.
Key advancements include:
- Integration of at-home, self-collection laboratory testing services
- Launch of a personalized therapy alternative to GLP-1 medications
- Improved pharmacy benefits infrastructure
Over the past 30 days, 38% of patients providing insurance information received affordable coverage for branded GLP-1 medication, with expectations to exceed 50% soon.
LifeMD (Nasdaq: LFMD), a leading virtual primary care provider, has announced its participation in three major investor conferences in September 2024. The company's management will attend:
1. H.C. Wainwright 26th Annual Global Investment Conference (Sept. 9-11) in New York, featuring a corporate presentation on Sept. 9 at 12:00 p.m. ET.
2. TD Cowen 9th Annual FutureHealth Conference (Sept. 10) in New York, participating in a panel discussion at 2:20 p.m. ET.
3. Cantor Fitzgerald Global Healthcare Conference (Sept. 17-19) in New York, with a fireside chat on Sept. 18 at 8:35 a.m. ET.
At these events, LifeMD's management will engage in one-on-one meetings with investors, showcasing the company's progress and future prospects in the virtual healthcare sector.
LifeMD (LFMD) reported strong Q2 2024 results, with revenue increasing 41% year-over-year to $50.7 million. Telehealth revenue grew 67%, and the segment achieved profitability one quarter ahead of guidance with adjusted EBITDA of $820,000. Key highlights include:
- Telehealth active subscribers increased 32% to 254,000
- Weight management subscribers exceeded 60,000
- Gross margin expanded to 90%
- Adjusted EBITDA increased 44% to $2.5 million
- Cash position of $35.7 million as of June 30, 2024
The company raised its 2024 telehealth revenue guidance to $150 million and introduced telehealth adjusted EBITDA guidance of $3-4 million. However, due to WorkSimpli's underperformance, consolidated adjusted EBITDA guidance was revised to $13-15 million.
LifeMD (Nasdaq: LFMD), a leading virtual primary care provider, has announced it will release its Q2 2024 financial results on August 7, 2024, after U.S. financial markets close. The company will host a conference call at 4:30 p.m. Eastern time on the same day to discuss the results. Investors can access the call via toll-free (1-800-245-3047) or international (1-203-518-9765) dial-in numbers, using the conference ID: LIFEMD. A live and archived webcast of the call will also be available.
